Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Hepatology

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally.
• HCC development involves complex, multi-step signaling pathway alterations.
• Understanding molecular pathways is crucial for effective HCC treatment.

Purpose of the Study:

• To review recent advancements in the role of the EGFR/PI3K/AKT/mTOR pathway in HCC.
• To assess the therapeutic potential of targeting this pathway in HCC.

Main Methods:

• Review of preclinical in vitro and in vivo studies.
• Analysis of molecular signaling cascades in hepatocarcinogenesis.

Main Results:

• The EGFR/PI3K/AKT/mTOR pathway is significantly implicated in HCC development.
• Targeting key components of this pathway demonstrated effectiveness in preclinical HCC models.

Conclusions:

• Inhibiting the EGFR/PI3K/AKT/mTOR pathway is a promising therapeutic strategy for HCC.
• Small molecule inhibitors targeting this pathway offer potential treatment options for HCC patients.